Cardioloxía
Servizo
Massachusetts General Hospital
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Massachusetts General Hospital (11)
2024
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Global Longitudinal Strain as Predictor of Inducible Ischemia in No Obstructive Coronary Artery Disease in the CIAO-ISCHEMIA Study
Journal of the American Society of Echocardiography, Vol. 37, Núm. 1, pp. 89-99
2023
-
Impact of Complete Revascularization in the ISCHEMIA Trial
Journal of the American College of Cardiology, Vol. 82, Núm. 12, pp. 1175-1188
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45
2022
-
Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial
Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661
2021
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
-
Natural History of Patients with Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study
Circulation, Vol. 144, Núm. 13, pp. 1008-1023
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392
2018
-
Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome
Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 538-544
2016
-
Cardiopatía isquémica en el VIH: profundizando en el conocimiento del riesgo cardiovascular
Revista Espanola de Cardiologia
2015
-
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF
Journal of the American Heart Association, Vol. 5, Núm. 3